Literature DB >> 3292373

Chemotherapy of myeloma: drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma.

D E Bergsagel1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292373     DOI: 10.1002/hon.2900060216

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  5 in total

1.  A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.

Authors:  J Bladé; J San Miguel; A Alcalá; J Maldonado; J García-Conde; M J Moro; M A Sanz Sanz; C Alonso; A Zubizarreta; C Besses
Journal:  Blut       Date:  1990-06

Review 2.  Problems in the management of myeloma.

Authors:  J S Malpas
Journal:  Postgrad Med J       Date:  1989-07       Impact factor: 2.401

3.  Trisomy 8 preceding diagnosis of acute nonlymphocytic leukemia by 2 years in a patient with multiple myeloma without cytological evidence of myelodysplasia.

Authors:  H J Weh; D Seeger; I Junge; D K Hossfeld
Journal:  Ann Hematol       Date:  1996-02       Impact factor: 3.673

Review 4.  Smoldering multiple myeloma requiring treatment: time for a new definition?

Authors:  Angela Dispenzieri; A Keith Stewart; Asher Chanan-Khan; S Vincent Rajkumar; Robert A Kyle; Rafael Fonseca; Prashant Kapoor; P Leif Bergsagel; Arleigh McCurdy; Morie A Gertz; Martha Q Lacy; John A Lust; Stephen J Russell; Steven R Zeldenrust; Craig Reeder; Vivek Roy; Francis Buadi; David Dingli; Suzanne R Hayman; Nelson Leung; Yi Lin; Joseph Mikhael; Shaji K Kumar
Journal:  Blood       Date:  2013-10-21       Impact factor: 22.113

5.  Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; O Mora; C Tinelli; D Valentini; S Brugnatelli; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; M Giordano; C Delfini; G Nicoletti; C Bergonzi; E Rinaldi; L Piccinini; E Ascari
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.